One of the most frequent monoclonal antibodies linked to MRONJ is Denosumab. In our study, attention was focused on different therapeutic approaches considering patients treated only with Denosumab or in combination with other drugs associated with the genesis of ONJ. We considered two different clinical approaches: sites treated without surgery; sites treated with traditional surgery or Er:YAG laser (2940nm, 250mJ, 20Hz). In our study, the discontinuation of the drug was evaluated in relation to treatment outcomes.
The present retrospective study we compared 507 sites of MRONJ occurred in 394 patients to highlight possible differences between cancer and non-cancer patients with stage III MRONJ.
Five hundred and seven sites of MRONJ were observed between January 2004 and March 2021 at the Center of Oral Medicine and Laser Surgery of the Academic Hospital of University of Parma. Patients were sub-classified in two groups: Group A (cancer) consisted in 293 affected patients and Group B (non-cancer) in 100 patients with MRONJ.
Both Group A and B were evaluated on: gender, mean age, underlying pathology and MRONJ stage.
This retrospective analysis highlighted no main differences between cancer and non-cancer patients with stage III MRONJ: both groups presented with similar percentage of advanced stage of MRONJ.
Contrary to general belief: osteometabolic patients are not to be considered "safe" from serious complications rather than cancer patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.